Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

After Running Lilly From China, CEO Says Local Commitment, Innovation Remain Priorities

This article was originally published in PharmAsia News

Executive Summary

For almost the entire month of March, Eli Lilly & Co. CEO John Lechleiter ran his company from China, a feat that included hosting Lilly's annual global leadership summit in Shanghai, where 150 high-level Lilly execs gathered to get a firsthand look at the country, visiting hospitals and research centers and meeting with government officials

You may also be interested in...



Five NCEs Approved In China In 2011: A Closer Look At SFDA’s Progress Report

China’s SFDA recently released its third annual drug registration report. The agency approved 718 drugs and APIs in 2011, including five NCEs.

Merck Launches FosaMax Plus In China; More Launches For Diabetes And Cardiovascular Drugs Expected

Following Eli Lilly’s launch of Forteo in China last November, Merck is launching FosaMax Plus, a vitamin D compounded version of its osteoporosis blockbuster FosaMax.

Emerging Views On Emerging Markets: The Sanford Bernstein Strategic Decisions Conference

In this periodic feature, PharmAsia News listens in at major industry events to what senior executives have to say about Asia and other emerging markets. For this profile, we zoom in on the Sanford Bernstein Strategic Decisions Conference, held June 1-2 in New York City.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC077822

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel